Integra LifeSciences amends and restates $1.65 billion credit facility
IART•Integra LifeSciences amended and restated a credit facility totaling approximately $1.65 billion, including $600 million revolving and term loan A facilities and a $450 million term loan B. It also closed a $450 million offering of 9.5% senior secured notes due 2033.
1. Debt refinancing
The amended facility includes a $600 million senior secured revolving credit facility and a $600 million senior secured term loan A, both maturing in five years, plus a $450 million senior secured term loan B maturing in seven years. Integra also closed a private offering of $450 million of 9.5% senior secured notes due 2033. Net proceeds and borrowings under the credit facility refinanced the existing facility and covered related fees and expenses.
